Introduction
Antibodies to prothrombin can be detected by enzyme-linked immunosorbent assay (ELISA) using prothrombin coated onto irradiated plates (aPT) or the phosphatidylserine/prothrombin complex as antigen (aPS/PT) and they have both been related with the clinical manifestation of APS. 1, 2 Current evidence supports the concept that they belong to distinct populations of autoantibodies. Nevertheless, they can both be detected simultaneously in one patient. 3 This mini-review will focus on data available on aPS/PT antibodies and their clinical utility in the diagnosis of antiphospholipid syndrome (APS).
Clinical utility of aPS/PT in the diagnosis of APS
The association between APS and antibodies to prothrombin, detected either as aPT or aPS/PT, has been evaluated with conflicting results. [4] [5] [6] [7] [8] However, emerging evidence supports the clinical utility of aPS/PT in the diagnosis of APS. 9 Early studies from Galli et al. 3 showed aPS/PT in 95% of their patients with thrombosis, but no differences in prevalence were found between those patients with thrombosis and those without. Funke et al. 10 reported that aPS/PT conferred an odds ratio (OR) of 2.8 for venous thrombosis and of 4.1 for arterial thrombosis in patients with systemic lupus erythematosus (SLE). In 2000, Atsumi et al. 1 supported these data by showing that the presence of aPS/PT conferred a 3.6-fold increase in the risk of APS in 265 Japanese patients with systemic autoimmune diseases.
Many subsequent reports have confirmed the association between aPS/PT and clinical manifestations of APS. 2, 9, 11, 12 Recent data from Zigon et al. 13 reported that aPS/PT was the strongest independent risk factor for the presence of antiphospholipid antibodies (aPL)-related obstetric complications in a cohort of 156 patients with systemic autoimmune diseases. Sanfelippo et al. 14 with accessible medical histories. These results support the concept that testing for aPS/PT in patients negative for aCL, anti-b2GPI and lupus anticoagulant (LA) can contribute to the identification of APS in those who may go otherwise undiagnosed based on current testing recommendations.
Data from our group also support the importance of aPS/PT as a diagnostic marker of APS. 8 We evaluated several possible specificities combinations aiming to identify the aPL profile yielding the best diagnostic accuracy for APS. This study included 230 SLE patients, all tested for six aPL deriving 23 possible combinations of results. The profile including LA þ anti-b2GPI þ aPS/PT held the best diagnostic accuracy for APS as a whole (OR 3.73) and, individually, for each, thrombosis (OR 3.75) and pregnancy loss (OR 4.82) and the best specificity when compared with all the other attainable combinations of tests, including the current classification criteria profile.
A recent systematic review suggested that routine measurement of aPS/PT (but not aPT) might be useful in establishing the thrombotic risk of patients with previous thrombosis and/or SLE. Antibodies to prothrombin (both aPT and aPS/ PT) were shown to increase the risk of thrombosis (OR 2.3 (95% confidence interval (CI) 1.72-3.5)) but aPS/PT seemed to represent a stronger risk factor for thrombosis, for both arterial and/or venous, than aPT (OR 5.11 (95% CI 4.2-6.3) and OR 1.82 (95% CI 1.44-2.75), respectively). 15 
aPS/PT and LA
In 1988, Fleck et al. 16 showed that aPT had LA activity. In addition, some antibodies responsible for LA activity bind to prothrombin in certain experimental conditions, [17] [18] [19] and prothrombin has been shown to be required for expressing LA activity in aCL-depleted LA-positive plasma samples. 17 Today it is widely accepted that antibodies to prothrombin, along with anti-b2GPI, are the major autoantibodies responsible for LA activity.
Based on a strong association between aPS/PT and LA, some published studies suggest that aPS/ PT may be a surrogate test for LA and, therefore, a 'LA-confirming property' was asserted for these antibodies. 7, 20, 21 Conversely, a recent paper from our group suggests that regardless of the high frequency of aPS/ PT, but not aPT, in patients with LA, their association with thrombosis seems to be independent from the presence of LA. 22 
aPS/PT as risk factors
It is widely accepted that the risk of thrombosis progressively increases with the increase in number of positive aPL tests. [23] [24] [25] [26] A recent retrospective evaluation including 230 patients with SLE reported that the combination of LA, anti-b2GPI and aPS/PT had the best diagnostic accuracy for APS. 8 Moreover, triple positivity for LA þ anti-b2GPI þ aPS/PT was more strongly associated with clinical events (thrombosis and/or pregnancy loss) when compared with double or single positivity for these antibodies.
Risk prediction models have great potential to support clinical decision making and many, such as the Framingham risk score, SCORE, QRISK, and the Reynolds risk score, have been developed for cardiovascular disease. 27, 28 In APS, three score systems have been formulated to quantify the risk of thrombosis/obstetric events, aiming to help physicians to stratify patients. 25, 29, 30 Two of these, the aPL score 29 and the Global Anti-Phospholipid Syndrome Score (GAPSS), 30 include antibodies to aPS/PT among the variables computed when assessing the risk for thrombosis or pregnancy morbidity. Positivity for aPS/PT was found to be an important variable when assessing the risk by using the GAPSS, suggesting that the addition of these antibodies can help in predicting APS-related clinical manifestations. Although promising, these tools need to be validated in independent larger cohorts.
Task force report on APS laboratory diagnostics and trends
A task force of worldwide scientists in the field recently met, discussed and analysed critical questions related to 'criteria' and 'non-criteria' aPL tests in an evidence-based manner during the 14th International Congress on Antiphospholipid Antibodies (APLA, 18-21 September 2013, Rio De Janeiro, Brazil). Based on available evidence, the group concluded that a) testing for aPS/PT might contribute to assess the risk of thrombosis; b) testing for aPS/PT might contribute to a better identification of patients with APS; and c) results (confirmed after multivariate analysis) do not substantially differ between groups, suggesting that aPS/PT are truly relevant in APS, 31 supporting the potential importance of testing for aPS/PT in routine practise. However, some methodological issues appertaining to all aPL are still under debate as subjects of major concern. Future studies focusing on harmonization and standardization of tests used to detect aPS/PT are urgently needed.
Conclusions
Although some controversial data still exist, most of the available studies support the association between aPS/PT and the clinical manifestations of APS. Many groups are currently working towards further characterization of aPS/PT and their mechanisms of action; additional laboratory and clinical studies, however, are needed to conclusively define the relevance and prognosis impact of testing for these antibodies in daily routine clinical practise.
The possibility of aPS/PT becoming an additional serological classification criterion for APS is under debate, especially when considering how to identify APS patients negative for classical aPL.
